Introduction
In both human and animal models, hypertension is associated with cardiac and aortic remodeling. [1] [2] [3] [4] Cardiac remodeling is defined as genome expression resulting in molecular, cellular and interstitial changes and manifested clinically as myocardial hypertrophy, fibrosis and cardiac decompensation. 1, 5 Aortic remodeling is characterized by impaired endothelium-dependent vasodilation and structural vascular changes; 6 thus, endothelium plays a primary role in the modulation of vascular tone and structure.
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The process of cardiac remodeling has been found to be influenced by hemodynamic load 9 and neurohormonal activation; unfortunately, the exact mechanism has not been fully elucidated. Vascular endothelium directly contacts flowing blood and transduces hemodynamic stimuli into changes in endothelial structure and function. 10 Hemodynamic shear stress from blood flow regulates vascular morphogenesis and blood pressure through the endothelium. 11 Recently, a rapid and significant downregulation of ET-1 mRNA and peptide release in bovine aortic endothelial cells upon hemodynamic shear stress was found, 12 but no in vivo evidence has been shown.
Drag-reducing polymers (DRPs) are long-chain, bloodsoluble macromolecules, which have been shown to greatly reduce frictional resistance in flow. 13 Previous studies have demonstrated that intravenous injection of even nanomolar concentration of DRPs increased hemodynamic shear stress 14, 15 and decreased peripheral vascular resistance. 16 In this study, we hypothesized that intravenous infusion of DRPs may improve left ventricular hypertrophy and aortic remodeling in spontaneously hypertensive rats (SHR) through increasing blood shear stress.
Materials and methods
Preparation of DrPs
DRP solution was prepared by polyethylene oxide (PEO; Sigma-Aldrich Co., St Louis, MO, USA), with an average molecular weight (MW) of 5×10 6 Da. The polymer was carefully dissolved in normal saline (NS) at a concentration of 1,000 ppm, avoiding mechanical shear degradation of the long-chain macromolecules, and then dialyzed against NS for 24 hours using a membrane (Regenerated Cellulose dialysis membrane, Spectra; Spectrum Laboratories Inc., NJ, USA) with 50-kDa MW cutoff. The stock PEO solution of 1,000 ppm concentration was diluted to a concentration of 20 ppm or 10 ppm with saline and mixed for 1 hour on a slow rocker prior to use.
animals and procedures
All experimental procedures in this study were approved by the Animal Care and Use Committee of the Southern Medical University (Guangzhou, Guangdong, People's Republic of China). The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication updated in 2011). In all, 24 male SHR (8-week old, 180-220 g, provided by the Vital River) were randomly divided into three groups: NS group (n=8), 10 ppm group (n=8) and 20 ppm group (n=8). One control group of age-matched male normotensive Wistar rats (WR) received NS. A syringe pump (TE311; Terumo Corporation, Tokyo, Japan) was utilized to guarantee a constant-rate infusion at 3 mL/h for 30 min via the rat tail vein every 2 days for 2 months. Rats were housed at constant room temperature, humidity and light cycles (12/12 h light-dark); had free access to tap water and were fed standard chow ad libitum. At 8 weeks with this treatment and after echocardiography measurements, animals were weighed and sacrificed with a lethal dose of sodium pentobarbital (60 mg/kg i.p.); blood samples were collected for the enzyme-linked immunosorbent assay (ELISA). Then, the heart was removed and the left ventricle (LV) was dissected. Some parts of LV tissue were snap frozen in liquid nitrogen and stored at −80°C for subsequent quantitative polymerase chain reaction (qPCR). The remaining tissues were fixed in 10% formalin, and paraffin was embedded for histological assessment.
DrP treatments
Sixteen male WR (250-300 g) were randomly and evenly divided into two groups, a DRP of 10 ppm group (WR + 10) and a saline group (WR + NS). The rats were anesthetized by intraperitoneal injection of pentobarbital sodium (45 mg/kg). After opening the abdominal cavity, an ultrasonic flow probe (Transonics Inc., Park City, UT, USA) was placed around the abdominal aorta 5 mm above the common iliac artery. NS or 10 ppm PEO was injected via the caudal vein at a constant rate of 5 mL/h for 20 min according to the assigned treatment group. Shear stress was calculated by the following equation:
where μ is the blood viscosity, Q is the flow velocity and d is the diameter of abdominal aorta.
Measurement of body weight (BW), heart rate (hr) and systolic blood pressure (sBP) BW, HR and SBP were measured at the beginning, 20th, 40th and 60th days of the experiment when all animals were in conscious conditions. SBP was measured in all rats using tail-cuff method. 17 Ambient temperature was maintained at 30°C. Before the measurement, the rats were trained to adapt themselves to the restraining cages and tail-cuff apparatus for the standard non-invasive tail-cuff. Transthoracic echocardiography was performed with the use of a high-resolution echocardiographic system (Sequoia 512; Acuson, Siemens, Germany) equipped with a 14-MHz linear transducer (17L5 probe; Acuson). The transducer was located overlying the chest to produce the optimal parasternal short axis two-dimensional images. A parasternal short-axis M-mode image at the papillary muscle level was acquired to measure the left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic posterior wall thickness (LVPWS) and left ventricular end-systolic posterior wall-depth (LVPWD). Left ventricular systolic function was also assessed from these measurements by calculating the left ventricle fractional shortening (LVFS) and the left ventricle ejection fraction (LVEF). LVFS and LVEF were calculated as follows:
The LV volume was calculated by the formula of Teichholz:
where V is the LV volume and D is the LV dimension. 18 
Measurement of plasma and myocardial endothelin (eT) level
Both plasma and homogenated myocardial ET levels were measured by using an ELISA kit (Biocalvin, Catalog No EIA-3600, Shanghai, People's Republic of China) according to the manufacturer's instructions.
histological assessment LV and thoracic aorta were fixed in 10% formalin, dehydrated, and then embedded in paraffin. Subsequently, 4 μm thick sections were cut and stained with hematoxylin and eosin or Masson's trichrome. The cross-sectional areas (CSAs) of cardiomyocytes and collagen volume fraction in left ventricle (LVCVF) were quantified from each group. The medial thickness of thoracic aorta was quantified from each group. All image analysis was performed in a blind manner using Image-Pro Plus (version 6.0; Media Cybernetics, Rockville, MD, USA).
rNa extraction and quantitative reverse transcription polymerase chain reaction (qrT-Pcr) analysis
Total RNA was isolated from snap-frozen LV samples with RNAiso Plus (TaKaRa, Dalian, People's Republic of China), and RNA was subjected to reverse transcription reaction using the PrimeScript reverse transcription reagent kit (DRR037A; TaKaRa) according to the manufacturer's protocols. Quantitative analysis of the change in expression levels was performed using SYBR Premix Ex Taq (DRR041A; TaKaRa) at ABI 7500 (Thermo Fisher Scientific, Waltham, MA, USA). Primers for ET-1 and β-actin were constructed with the help of ShengGong Bio-Tech Co. (Shanghai, People's Republic of China). The primer sequences for polymerase chain reaction (PCR) were as follows: ET-1, 5′-CTGGACATCATCTGGGTCAA-3′ and 5′-CTGTTCCCTTGGTCTGTGGT-3′, 122 bp and β-actin, 5′-TGTCACCAACTGGGACGATA-3′ and 5′-GGGG TGTTGAAGGTCTCAAA-3′, 165 bp.
The alteration in mRNA expression in rats treated with DRPs or NS was assessed by the 2 −∆∆C t method.
statistical analysis
Values are expressed as mean ± standard error of the mean (SEM). Statistical significance between multiple groups was determined by using one-way analysis of variance (ANOVA), followed by the Bonferroni's multiple comparison test for comparisons between groups. P,0.05 was considered to be a statistically significant difference.
Results
BW, hr and sBPs
During 60 days of treatment, BW in SHR and WR groups (n=8 per group) increased over time, and there were no significant differences (data not shown). SBP in the WR + NS group was significantly lower than SBP in all SHR groups (n=8 per group; Figure 1 ), while there was no significant difference between the SHR + NS, SHR + 10DRP and SHR + 20DRP groups. HR did not differ among all groups (data not shown).
DrPs improve shear stress of abdominal aortic flow
Abdominal aortic flow was significantly higher in the WR group treated with 10 ppm PEO compared to the saline-treated group (n=8 per group, P,0.05; Figure 2A) . What is more, the change of shear stress in abdominal aorta was markedly higher Figure 2B ).
DrPs improve left ventricular posterior wall hypertrophy
After 60 days treatment, M-mode echocardiography was conducted in vitro to assess myocardial hypertrophy (n=8 per group; Figure 3A) . The results showed significant increase in LVPWS (3.31±0.21 vs 2.62±0.11, respectively; P=0.015; n=8 per group; Figure 3 ) and LVPWD (2.58±0.05 vs 1.91±0.11, respectively; P=0.002; n=8 per group; Figure 3E ) in the SHR + NS group compared with the WR + NS group. However after DRP administration, the LVPWS of rats in the SHR + 10DRP and SHR + 20DRP groups was significantly decreased compared with that of rats in the SHR + NS group (2.65±0.12 and 2.63±0.14 vs 3.31±0.21, P=0.002 and P=0.017, respectively; n=8 per group; Figure 3D ). What is more, the LVPWD of rats in the SHR + 20DRP group was significantly decreased compared with that of rats in the SHR + NS group (2.03±0.14 vs 2.58±0.05, respectively; P=0.011; n=8 per group; Figure 3E ). Besides, LVESD and LVEDD of rats in the SHR + 10DRP and SHR + 20DRP groups were significantly increased compared with those of rats in the SHR + NS group (n=8 per group; Figure 3B and C), while there was no significant difference in fractional shortening (FS) and ejection fraction (EF; n=8 per group; Figure 3F and G).
DrPs prevent left ventricular hypertrophy and myocardium fibrosis
As shown in Figure 4A and B, there was a significant increase in CSA in the SHR + NS group compared with the Figure 4A and B). Masson's trichrome staining clearly showed increased LVCVF in the SHR + NS group compared with the WR + NS group (6.58%±0.49% vs 1.86%±0.37%, respectively; P=0.0002; n=3 per group; Figure 4C and D) . These changes were significantly reversed in the SHR + 10DRP and SHR + 20DRP groups (2.70%±0.34%, 2.38%±0.34% vs 6.58%±0.49%; P=0.001 and P=0.0004, respectively; n=3 per group; Figure 4C and D), but without significant differences between them (n=3 per group; Figure 4C and D).
DrPs improve aortic medial thickness
As shown in Figure 5 , the medial thickness of aorta in the SHR + NS group was significantly higher than that in the WR + NS group (164.97±3.37 μm vs 126.63±4.01 μm, respectively; P=0.002; n=4 per group; Figure 5A and B). The treatment with DRPs significantly reduced the medial thickness in the SHR + 10DRP and SHR + 20DRP groups (132.73±7.12 μm, 135.46±6.79 μm vs 164.97±3.37 μm; P=0.009 and P=0.017, respectively; n=4 per group; Figure 5A and B).
DrPs attenuate eT-1 expression in lV and aorta
Immunohistochemistry clearly showed increased expression of ET-1 protein in the cardiomyocytes and aorta of rats in the SHR + NS group compared with in the WR + NS group, which was attenuated by DRP administration in the SHR + 10DRP and SHR + 20DRP groups (n=3 per group; Figure 6A and B). Real-time PCR showed that ET-1 gene expression was markedly decreased in the SHR + 20DRP group compared with in the SHR + NS group (1.46±0.14 vs 2.24±0.07, respectively; P=0.001; n=3 per group; Figure 6C ). These results were in parallel with the left ventricular tissue and serum ET levels (n=8 per group; Figure 6D and E).
Discussion
Although DRPs have shown potent hydrodynamic effects to increase blood flow and decrease vascular resistance, it is still unknown whether increased blood flow would affect ET-1 expression and cardiac/aortic remodeling. In this study, we assessed the effect of DRPs in the process of cardiac and aortic remodeling caused by hypertension and demonstrated that blood shear stress and ET-1 expression may play 
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effects of DrPs on left ventricular hypertrophy and aortic remodeling important roles in cardiac/aortic remodeling. To our best knowledge, this is the first report showing chronic administration of DRPs into the systemic circulation improves the cardiac and aortic remodeling, by increasing blood shear stress and suppressing the ET-1 expression.
DRPs are long-chain, blood soluble macromolecules, which have been shown to greatly reduce frictional resistance in both turbulent and laminar flow, known as Toms effect. 13, 19 DRPs were initially used in fire fighting, irrigation and petroleum pumping to reduce frictional energy losses in large pipes. Recently, these observations have been extended to the vascular system and some biological effects of DRPs have been reported. It was found that acute administration of nanomolar concentration of DRPs improved LV function in the rat model of myocardial infarction. 20 DRPs also enhanced microvascular perfusion in vivo. In a canine model of flowlimiting coronary artery stenosis, DRPs improved perfusion to myocardium by decreasing microvascular resistance through an increase in capillary volume and red blood cell (RBC) velocity. 21 In our study, DRPs significantly increased blood flow and blood shear stress (Figure 2) .
The family of ETs consists of four closely related peptides -ET-1, ET-2, ET-3 and ET-4 -which originate from large preproendothelin peptides and are synthesized 
Q d
/ , where μ is the blood viscosity, Q is the flow velocity and d is the diameter of abdominal aorta. Mean ± seM, n=8 per group and *P,0.05 compared with Ns. Abbreviations: DrP, drag-reducing polymer; shr, spontaneously hypertensive rats; Ns, normal saline; PeO, polyethylene oxide; seM, standard error of the mean.
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Zhang et al by endothelial and smooth muscle cells, as well as neural, renal, pulmonal and inflammatory cells. 22 ET-1 promotes vasoconstriction and cell proliferation. 23 The factors modulating the expression of ET-1 are shear stress, pulsatile stretch, epinephrine, angiotensin II and inflammatory cytokines. Shear stress induces rapid and significant downregulation of ET-1 mRNA expression and peptide release with respect to static conditions in bovine aortic endothelial cells and human umbilical vein endothelial cells. 24, 25 ET-1 plays an important role in hypertension. Besides its blood pressure raising effect in human beings, ET-1 induces vascular and myocardial hypertrophies, which are independent risk factors for cardiovascular morbidity and mortality. 26, 27 In experimental hypertension, vascular ET-1 content is much more enriched than is plasma, which promotes vasoconstriction and smooth muscle cell proliferation via ETA receptors. 28 As we can see from Figure 5 , ET-1 expression in left ventricular and thoracic aorta of the SHR + NS group was significantly higher compared with that of the WR + NS group. Moreover, in experimental hypertension, treatment with a selective ETA-receptor antagonist attenuated left ventricular hypertrophy, prevented vascular hypertrophy and ameliorated endothelial dysfunction. 29 In our study, intravenous infusion of DRPs significantly increased blood shear stress, which may suppress ET-1 expression in left ventricular and thoracic aorta and left ventricular hypertrophy and aortic remodeling (Figures 3-5) .
It should be noted that the sample size in this study is relatively small with some significant variation in some of the data, and this would inevitably weaken the results and might be the reason why no difference is seen between the two groups (SHR + 10DRP and SHR + 20DRP).
Conclusion
This work demonstrated for the first time that chronic intravenous infusion of DRPs significantly improved cardiac and 
